Hikma Pharmaceuticals PLCLSE: HIK

Hikma Pharmaceuticals: Director/PDMR Shareholding

· Issued by Hikma Pharmaceuticals PLC via RNS

Summary by 6ix AI

Hikma Pharmaceuticals PLC was notified that Bassam Kanaan, a person discharging managerial responsibilities (a senior manager whose share dealings must be disclosed), sold ordinary shares of 10 pence each in the company on the London Stock Exchange on November 5 and November 6, 2026.

Key details

  • On November 5, 2026, he sold 61,941 shares at £16.92 each, for a total of £1,048,041.72.
  • On November 6, 2026, he sold 5,000 shares at £16.50 each, for a total of £82,500.

6ix AI wrote this summary from the release below and checked it against the release.

Hikma Pharmaceuticals Plc
09 November 2026

Hikma Pharmaceuticals PLC

(the “Company”)

LONDON, 9 November 2026: Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) announces it has been notified of the following transactions by a Person Discharging Managerial Responsibilities (“PDMR”) of the Company.

This notification is made under Article 19(1) of the EU Market Abuse Regulation 596/2014 as it forms part of domestic law by virtue of the European Union (Withdrawal) Act 2018 ("MAR"). The information set out below is provided in accordance with the requirements of Article 19(3) of MAR.

Notification and public disclosure of transactions by Person Discharging Managerial Responsibilities

1

Details of the person discharging managerial responsibilities / person closely associated

a)

Name

Bassam Kanaan

2

Reason for the notification

a)

Position/status

PDMR

b)

Initial notification /Amendment

Initial notification

3

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

Hikma Pharmaceuticals PLC

b)

LEI

549300BNS685UXH4JI75

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Disposal of Shares in Hikma Pharmaceuticals PLC

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.92

61,941

d)

Aggregated information

Price(s): £16.92

Volume(s): 61,941

Total: £1,048,041.72

e)

Date of the transaction

5 November 2026

f)

Place of the transaction

London Stock Exchange (XLON)

4

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument, type of instrument and identification code

Description: Ordinary shares of 10 pence each (Shares)

ID Code: GB00B0LCW083

b)

Nature of the transaction

Disposal of Shares in Hikma Pharmaceuticals PLC

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£16.50

5,000

d)

Aggregated information

Price(s): £16.50

Volume(s): 5,000

Total: £82,500

e)

Date of the transaction

6 November 2026

f)

Place of the transaction

London Stock Exchange (XLON)

Helen Middlemist

Group Company Secretary
+44 (0) 20 7399 2760

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

Hikma Pharmaceuticals PLC on 6ix

Earlier from Hikma Pharmaceuticals

All Hikma Pharmaceuticals news releases